# Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

> **NCT00598312** · PHASE3 · COMPLETED · sponsor: **Oakwood Laboratories, LLC** · enrollment: 201 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Leuprolide Acetate for Injectable Suspension

## Key facts

- **NCT ID:** NCT00598312
- **Lead sponsor:** Oakwood Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2010-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00598312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00598312, "Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00598312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*